logo

Veru Inc. (VERU)



Trade VERU now with
  Date
  Headline
2/13/2019 6:36:13 AM VERU Q1 Net Loss $2.1 Mln Or $0.03/Shr Vs Loss $4.3 Mln Or $0.08/Shr Last Year
1/22/2019 8:34:40 AM Veru Initiates First Patient In A Clinical Trial Of Prostate Cancer Drug, VERU-111
12/13/2018 6:33:09 AM Veru Inc. Q4 Net Loss $7.9 Mln Or $0.14/Shr Vs Loss $4.7 Mln Or $0.10/Shr Last Year
12/3/2018 8:36:48 AM Veru Says First Patient Dosed In Bioequivalence Clinical Trial For Combination Tadalafil – Finasteride Tablet
10/1/2018 7:34:08 AM Veru Enrolls First Patient In Phase 2 Study Of Zuclomiphene Citrate For Hot Flashes Caused By ADT
9/27/2018 9:07:08 AM Veru Announces Pricing Of Underwritten Public Offering Of 7.14 Mln Shares At $1.40/shr
9/26/2018 4:06:57 PM Veru Announces Proposed Public Offering Of Common Stock
8/14/2018 6:32:55 AM Veru Q3 Net Loss $7.9 Mln Or $0.15/Shr
6/12/2018 8:37:47 AM Veru To Start Phase 2 Trial Of Cis-Clomiphene Citrate To Treat Hot Flashes Caused By Advanced Prostate Cancer Therapy
5/17/2018 8:33:56 AM Veru Announces Publication Of Data From Preclinical Studies Of VERU-111
5/17/2018 8:20:20 AM Veru Announces Publication Of Data On Oral VERU-111 In Prostate Cancer In Connection With 2018 ASCO Annual Meeting
5/9/2018 6:36:29 AM Veru Q2 Net Loss $3.8 Mln Or $0.07/Shr Vs Loss $1.8 Mln Or $0.06/Shr Last Year
5/3/2018 8:43:30 AM Veru Announces Presentation Of Data Showing Efficacy Of VERU-111 In Taxane Resistant Human Prostate Cancer Model
3/22/2018 8:33:03 AM FDA Grants Fee Waiver For Tamsulosin DRS NDA; Provides $2.4 Mln For Drug Product Development
3/16/2018 8:35:20 AM Veru Announces Presentation Of Data Demonstrating Efficacy Of VERU-111 In Taxane Resistant Human Prostate Cancer Model
2/14/2018 6:32:38 AM Veru Q1 Loss Per Share $0.08 Vs Loss $0.04 Last Year